PRODUCT PIPELINE OVERVIEW
The pet health industry provides numerous market advantages over human health in that new medicines can be developed in significantly less time and in a very cost efficient manner.
A significant advantage is that veterinary medicine animal health products do not face the same post-patent expiration cliff or generic competition as human pharmaceutical products.
Furthermore, the industry has limited exposure to government or third party payer risk and pet owners are eager to purchase state of the art medicines for their pets, who are increasingly seen as family members.
Moreover, new product development within animal health is supported by less expensive and less risky R&D cycles. These factors should translate to highly sustainable growth for the animal health industry.
Poïesis has agreed to licensing terms to acquire the veterinary IP rights for assets focused on the treatment of cancers in dogs and cats.
We are working closely with the biotechnology company that is developing this product for use in humans, which allows Poïesis unprecedented access to data and drug product for clinical trials.
We continue to evaluate novel therapeutics that we encounter which may address unmet or poorly served needs in the pet medicines market.
Poïesis has identified a number of opportunities to develop diagnostic tests that would be complementary to the assets we plan to develop in our therapeutic pipeline.